Clinical Trials Results
Results for the search you initiated will be displayed below.
Trial Name
Brief Summary
This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy
versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung
cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin,
pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. The purpose of this trial is to find out if the addition
of pembrolizumab to usual chemotherapy is better or worse than usual chemotherapy alone for
non-small cell lung cancer.
This phase III ALCHEMIST trial studies genetic testing in screening patients with stage
IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the
genes in a patient's tumor cells may help doctors select the best treatment for patients that
have certain genetic changes.
This trial studies the side effects of pembrolizumab with or without chemotherapy in treating
patients with stage IV non-small cell lung cancer that has come back (recurrent) and has
spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such
as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed
and carboplatin, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
pembrolizumab with or without chemotherapy may shrink the tumor in older patients with
non-small cell lung cancer.
This phase II trial studies how well osimertinib works in treating patients with non-small
cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back.
Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed
by pemetrexed and carboplatin with or without pembrolizumab after disease progression is
superior to induction with pembrolizumab, pemetrexed and carboplatin followed by
pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous
non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab,
may help the body's immune system attack the cancer, and may interfere with the ability of
tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and
carboplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or
without pembrolizumab works better in treating patients with non-squamous non-small cell
cancer.
This phase III trial studies how well an antibody (durvalumab) with chemotherapy and
radiation therapy (chemoradiation) works in treating patients with stage III non-small cell
lung cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal
antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. This study is being done to see
if adding durvalumab to standard chemoradiation followed by additional durvalumab can extend
patients life and/or prevent the tumor from coming back compared to the usual approach of
chemoradiation alone followed by durvalumab.
This phase III trial compares the effect of bevacizumab and AZD9291 (osimertinib) combination
vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside
of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR
protein is involved in cell signaling pathways that control cell division and survival.
Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal
amounts on some types of cancer cells. This causes cancer cells to divide more rapidly.
Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell
growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with
the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may
control cancer for longer and help patients live longer as compared to osimertinib alone.
This phase II trial compares cabozantinib alone and the combination of cabozantinib and
nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small
cell lung cancer (NSCLC). Cabozantinib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may
interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as
docetaxel, gemcitabine hydrochloride, paclitaxel, and nab-paclitaxel, work in different ways
to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving cabozantinib alone or in combination
with nivolumab may be more effective than standard chemotherapy in treating patients with
non-small cell lung cancer.
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Genetic
tests look at the unique genetic material (genes) of patients' tumor cells. Patients with
genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more
from treatment which targets their tumor's particular genetic abnormality. Identifying these
genetic abnormalities first may help doctors plan better treatment for patients with solid
tumors, lymphomas, or multiple myeloma.
This randomized phase II/III trial studies how well whole-brain radiation therapy works and
compares it with or without hippocampal avoidance in treating patients with small cell lung
cancer that is found in one lung, the tissues between the lungs, and nearby lymph nodes only
(limited stage) or has spread outside of the lung in which it began or to other parts of the
body (extensive stage). Radiation therapy uses high energy x-rays to kill tumor cells and
shrink tumors. The hippocampus is part of the brain that is important for memory. Avoiding
the hippocampus during whole-brain radiation could decrease the chance of side effects on
memory and thinking. It is not yet known whether giving whole-brain radiation therapy is more
effective with or without hippocampal avoidance in treating patients with small cell lung
cancer.
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or
without local consolidation therapy works in treating patients with stage IV non-small cell
lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium,
erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Local consolidation therapy such as radiation/stereotactic body radiation or
surgery may kill cancer cells left after initial treatment. Giving maintenance chemotherapy
and local consolidation therapy together may work better than maintenance chemotherapy alone
in treating patients with stage IV non-small cell lung cancer.
This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a
combination of different biomarker/ALK inhibitors work in treating patients with stage IV ALK
positive non-squamous non-small cell lung cancer. Lorlatinib, ceritinib, alectinib,
brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed,
cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading. It
is not yet known whether a combination of biomarker/ALK inhibitors or chemotherapy may work
better in treating patients with ALK positive non-squamous non-small cell lung cancer.
This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation)
with or without atezolizumab works in treating patients with limited stage small cell lung
cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Radiation therapy uses high energy
x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such
as atezolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving chemoradiation with or without
atezolizumab may work better in treating patients with limited stage small cell lung cancer.
This phase II/III trial compares the effect of adding radiation therapy to the usual
maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already
received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has
spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy
with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack
the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation
therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation
therapy in addition to atezolizumab may extend the time without extensive small cell lung
cancer growing or spreading compared to atezolizumab alone.
This randomized phase II trial studies how well carboplatin and paclitaxel with or without
ramucirumab work in treating patients with thymic cancer that has spread to other places in
the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as
carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to
grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without
ramucirumab will work better in treating patients with thymic cancer.
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic
cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in
treating patients with small cell lung cancer. MRI scans are used to monitor the possible
spread of the cancer with an MRI machine over time. PCI is radiation therapy that is
delivered to the brain in hopes of preventing spread of cancer into the brain. The use of
brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan.
Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer)
may be at least as good as the combination of PCI with MRI scans.
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with
genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV
non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.
This trial studies how well atezolizumab added to the usual radiation therapy works in
treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal
antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as
stereotactic body radiation therapy, uses special equipment to position a patient and deliver
radiation to tumors with high precision. This method can kill tumor cells with fewer doses
over a shorter period and cause less damage to normal tissue. Giving atezolizumab and
radiation therapy may work better than radiation therapy alone in treating patients with
early non-small cell lung cancer.
This phase II trial studies whether atezolizumab in combination with talazoparib works better
than atezolizumab alone as maintenance therapy for patients with SLFN11-positive
extensive-stage small cell lung cancer. Immunotherapy with monoclonal antibodies, such as
atezolizumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. PARPs are proteins that help repair damage to DNA,
the genetic material that serves as the body's instruction book. Changes (mutations) in DNA
can cause tumor cells to grow quickly and out of control, but PARP inhibitors like
talazoparib may keep PARP from working, so tumor cells can't repair themselves, and they stop
growing. Giving atezolizumab in combination with talazoparib may help lower the chance of
extensive-stage small cell lung cancer growing and spreading compared to atezolizumab alone.
This trial studies the side effects of radiation therapy followed by atezolizumab in treating
patients with stage II or III non-small cell lung cancer. Hyperfractionated radiation therapy
delivers smaller doses of radiation therapy over time and may kill more tumor cells and have
fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help
the body's immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. The purpose of this study is to test the safety and effectiveness of
radiation therapy followed by atezolizumab and find out what side effects, if any, it has on
patient's non-small cell lung cancer.
Clinical Trial Categories:
- Bone Cancer
- Brain Cancer
- Breast Cancer
- Cancer Control
- Companion Studies
- Gastrointestinal Cancer
- Genitourinary Cancer
- Gynecology (GYN) Cancer
- Head and Neck Cancer
- Leukemia
- Lung Cancer
- Lymphoma (Hodgkin's Disease, Non-Hodgkin's Lymphoma)
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndrome (MDS)
- Other Cancer Protocols
- Pancreas Cancer
- Sarcoma
- Skin Cancer
- Symptom Management